Consultation responses on the future reimbursement status of 5 combination products in ATC groups C07, C08 and C09

02 February 2009

The Danish Medicines Agency’s assessment of the future reimbursement status of 5 combination products in ATC groups C07, C08 and C09 for the treatment of cardiovascular diseases has been submitted for consultation with 11 December 2008 as the consultation deadline.

The Danish Medicines Agency has received four consultation responses, which were all submitted by companies ( Abbott, AstraZeneca, Paranova and Servier ). In the factbox to the right, there is a link to the consultation responses (in Danish only). Here, you can also find a link to the Danish Medicines Agency’s message of 25 November 2008 containing further details about the assessment.

The Danish Medicines Agency will include the submitted consultation responses in the final decision on the future reimbursement status of medicinal products for cardiovascular disease in ATC groups C02, C03, C07, C08 and C09 (blood pressure medicine).

For further information, please contact the Reimbursement department at medicintilskud@dkma.dk.

Danish Medicines Agency, 2 February 2009

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.